Quanterix Reports 29% Revenue Decline and $30M Net Loss in Q2 2025

Quanterix Corporation reported a significant decline in financial performance for the second quarter of 2025, with total revenues of $24.5 million, a decrease of 29% compared to $34.4 million in the same period last year. The company's product revenue fell to $16.8 million, down 15% from $19.9 million, primarily due to reduced demand from academic and pharmaceutical customers amid a slowdown in U.S. federal research funding and changing macroeconomic conditions. Service revenue also saw a substantial drop of 48%, totaling $7.1 million, largely attributed to the completion of a collaboration agreement with Eli Lilly and Company in 2024, which had previously generated significant revenue.

The company's operating expenses surged to $48.4 million, a 46% increase from $33.2 million in the prior year, driven by a $7.7 million charge related to impairment and restructuring costs, including a goodwill impairment of $6.4 million. This resulted in a net loss of $30.0 million for the quarter, compared to a loss of $7.4 million in the same quarter of 2024. The increase in losses was also influenced by higher selling, general, and administrative expenses, which rose by 30% to $31.4 million, reflecting non-recurring costs associated with acquisitions.

In terms of strategic developments, Quanterix completed the acquisition of Emission, Inc. in January 2025, which is expected to enhance its product offerings in the multiplex market segment. The company also finalized the acquisition of Akoya Biosciences, Inc. on July 8, 2025, aiming to expand its capabilities in spatial biology solutions. These acquisitions are part of Quanterix's strategy to integrate complementary technologies and enhance its market position. The company reported an installed base of over 1,000 Simoa instruments, with expectations for increased consumables revenue as the installed base grows.

Operationally, Quanterix's cash and cash equivalents stood at $132.9 million as of June 30, 2025, with marketable securities totaling $128.3 million. The company anticipates continued operating losses through at least the next 12 months, driven by ongoing investments in research and development, as well as costs associated with the integration of recent acquisitions. However, management expects that the synergies from the Akoya acquisition will help the combined company achieve cash flow breakeven by 2026.

Looking ahead, Quanterix plans to launch its Simoa One instrument by the end of 2025, which is expected to bolster instrument sales. The company remains focused on expanding its research and development efforts, enhancing its product offerings, and navigating the current economic challenges to stabilize its financial performance.